$COSM - The company is installing robotics and AI-driven automation and says the infrastructure is being built to support $100M+ in annualized revenue capacity. 🚨👇 Zacks Small-Cap Research initiated coverage earlier in 2026 with a $4.50 price target. Their thesis centered on COSM's pharmaceutical distribution base, acquisitions, manufacturing expansion and expected future revenue growth. COSM reported Q2 2026 revenue of about $19.0M, bringing first-half revenue to $36.9M, roughly +30% YoY. Q2 adjusted gross profit also increased substantially, while liabilities declined and shareholder equity improved. The company has maintained its $90M+ 2026 revenue target, versus $65.3M for FY2025. That's roughly 38% growth if achieved. COSM says its wholly owned pharmaceutical-distribution subsidiary CosmoFarm generated more than $15M of Q2 revenue, equivalent to a $60M+ annualized run rate. Revenue has increased roughly 4.3× since Cosmos acquired it. CosmoFarm now serves a network of 1,130+ pharmacies and works with roughly 250 pharmaceutical manufacturers/wholesalers. 🔥COSM owns Cana Laboratories, a pharmaceutical manufacturer founded in 1928 that has historically worked with major companies including AstraZeneca, Janssen, Merck, Viatris, Nestlé, Unilever and P&G. Earlier this year, Cana's contract-manufacturing orderbook was around 12M units. By September it had climbed to: 32.7+ MILLION contracted units. COSM says those contracts imply $20M+ in revenue and approximately $18M in gross profit over the lives of the contracts. 👀🚨FOR SHAREHOLDERS👇🚀 💰COSM's board authorized a share-repurchase program of up to $5 million. The authorization runs through December 31, 2026, unless extended. 🌊COSM says it retired its $8M ATW convertible note approximately 12 months early. According to the company's September corporate update: No further conversions / dilution from that instrument. COSM also reported that first-half liabilities fell 13.3%, while stockholders' equity increased 12.2%. COSM also emphasized that it currently has no ATM, no shelf registration and no floorless warrants in its September update. COSM has been developing CCX0722, its proprietary hydrogel-based weight-management platform. This isn't completely new—the project has been under development for years—but the strategy around it changed significantly in September. On September 14, COSM announced plans to explore tokenizing the intellectual property associated with CCX0722, describing it as a potentially non-dilutive financing structure. COSM has also advanced international patent protection for the platform across: United States Europe Canada Australia The potentially bullish concept is that COSM could finance/develop the asset without simply issuing more COSM shares. COSM entered animal health On September 9, COSM launched C-ScrubVet in the United Kingdom. That pushes the company's infection-control products into veterinary applications and gives it exposure to the animal-health market. It's another example of COSM trying to monetize existing manufacturing/product capabilities across additional markets rather than building everything from scratch. COSM announced that it purchased approximately $300,000 of ETH in September. COSM owns ~475 ETH + 15.66 BTC, currently worth ~$2.6M total. On October 1, COSM said its portfolio now consists of 15+ proprietary brands/product lines plus 10 branded generics, distributed across 40+ countries in Europe, the Middle East, North America and Asia. COSM claims the categories it operates in collectively represent roughly $946B of addressable global markets.

Went back into the Dumbledore scene in Tsuki's clip. There's more hiding in it 🐈‍⬛ 1. The UNO sits on Dumbledore > 1:21, an uno reverse appears over Dumbledore, seconds before the Time-Turner > it's not in the movie, Tsuki added it > reverse + Time-Turner = go back 2. The line Tsuki cut The clip starts at “ If you succeed tonight “. The line right before it in the film: “ Three turns should do it, I think “ → in the book Dumbledore leaves at 5 to midnight, 11:55pm → three turns = three hours back = 8:55pm → Nat Turner's 10,462 share Form 4 hit the SEC Thu 1 Oct, 8:55pm ET → & 3 days back from the clip (Sun 4 Oct) = Thu 1 Oct, the day he bought Three turns either way lands on Turner & 10462 → 10/4 · 6/2. Tsukis clip uno & RK's uno 3. The rescue date • in the story, the rescue night is Monday 6 June 1994 • exactly 30 years later, Thu 6 June 2024, RK's livestream gets scheduled • a Time-Turner is an hourglass • 30 days is the SEC's clock & the gap between Tsuki's “ 4663 “ & the clip • 855 days on from 6 June 2024 = Fri 9 Oct Retrace the steps $TSUKI $GME cc: @tsukionsolana @TheRoaringKitty @natsturner

AMC's $3.97B refinancing is expected to close Monday, biggest balance-sheet event of their year. $AMC The deal (priced Sep 23): $2.0B of 8.875% notes due 2031 + $850M term loan at SOFR + 4.50% + a $1.12B second-lien facility with Deutsche Bank. Proceeds kill the 2029 senior notes, Muvico's $903.4M notes, and the old term loans. Worth noting the cost: they locked in 8.875% with the 10-year at ~5.24%, highest since 2007. This runway isn't cheap. - Q2 beat: $1.60B revenue (+14.2%), EPS $0.14 vs $0.03 loss expected, EBITDA +69.6%, net loss narrowed to $11.4M - Citi raised PT to $2.20 (still a Sell) — ~21% below the $2.77 close - Stock hit $3.35 intraday during the refi rally, 52-week range $0.93–$3.40 - Watch item: shareholders doubled the equity incentive plan to 50M shares at the Sep 24 meeting but rejected say-on-pay — dilution risk is back on the table